EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

18 F‐fluoro‐ethyl‐tyrosine PET co‐registered with MRI in patients with persisting acromegaly

Leontine E H Bakker, Marco J T Verstegen, Diandra C Manole, Huangling Lu, Thomas J M Decramer, Iris C M Pelsma, Mark C Kruit, Berit M Verbist, Annenienke van de Ven, Mark Gurnell iD, Idris Ghariq, Wouter R van Furth und 2 weitere

Clinical Endocrinology · 2024-08 · 101 (2) · 142-152

DOI: 10.1111/cen.15079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology, online erschienen am 31.05.2024. Verfasst von Leontine E H Bakker und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Acromegaly, Magnetic Resonance Imaging, Tyrosine. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Mark Gurnell is supported by the NIHR Cambridge Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To report our experience with 18 F‐fluoro‐ethyl‐tyrosine (FET) positron emission tomography‐computed tomography (PET‐CT) co‐registered with magnetic resonance imaging (MRI) (FET‐PET/MRI CR ) in the care trajectory for persistent acromegaly.

Design

Prospective case series. Patients Ten patients with insufficiently controlled acromegaly referred to our team to evaluate surgical options.

Measurements

FET‐PET/MRICR was used to support decision‐making if MRI alone and multidisciplinary team evaluation did not provide sufficient clarity to proceed to surgery.

Results

FET‐PET/MRI CR showed suspicious (para)sellar tracer uptake in all patients. In five patients FET‐PET/MRI CR was fully concordant with conventional MRI, and in one patient partially concordant. FET‐PET/MRI CR identified suggestive new foci in four other patients. Surgical re‐exploration was performed in nine patients (aimed at total resection (6), debulking (2), diagnosis (1)), and one patient underwent radiation therapy. In 7 of 9 (78%) operated patients FET‐PET/MRI CR findings were confirmed intraoperatively, and in six (67%) also histologically. IGF‐1 decreased significantly in eight patients (89%). All patients showed clinical improvement. Complete biochemical remission was achieved in three patients (50% of procedures in which total resection was anticipated feasible). Biochemistry improved in five and was unchanged in one patient. No permanent complications occurred. At six months, optimal outcome (preoperative intended goal achieved without permanent complications) was achieved in six (67%) patients and an intermediate outcome (goal not achieved, but no complications) in the other three patients.

Conclusions

In patients with persisting acromegaly without a clear surgical target on MRI, FET‐PET/MRI CR is a new tracer to provide additional information to aid decision‐making by the multidisciplinary pituitary team.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcromegalyMagnetic Resonance ImagingTyrosineHumansMaleFemaleMiddle AgedAdultProspective StudiesPositron-Emission TomographyPositron Emission Tomography Computed TomographyAgedInsulin-Like Growth Factor I

Stichwörter der Autor:innen

18F‐fluoro‐ethyl‐tyrosineacromegalyfunctional imagingmultidisciplinary teampositron emission tomographysurgical decision makingtranssphenoidal surgery

Substanzen

TyrosineO-(2-fluoroethyl)tyrosineInsulin-Like Growth Factor I

Autor:innen und Institutionen

  • Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.
  • Center for Endocrine Tumors Leiden (CETL), Pituitary Center, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Neurosurgery, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Neuroendocrinology, National Institute of Endocrinology CI Parhon, Bucharest, Romania.
  • Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Neurosurgery, University Hospitals Leuven, Leuven, Belgium.

ORCID-Profile: Mark Gurnell

Förderung

  • Mark Gurnell is supported by the NIHR Cambridge Biomedical Research Centre

Zitieren

APA

Bakker, L. E. H., Verstegen, M. J. T., Manole, D. C., Lu, H., Decramer, T. J. M., Pelsma, I. C. M., Kruit, M. C., Verbist, B. M., van de Ven, A., Gurnell, M., Ghariq, I., van Furth, W. R., Biermasz, N. R., & Pereira Arias-Bouda, L. M. (2024). 18 F‐fluoro‐ethyl‐tyrosine PET co‐registered with MRI in patients with persisting acromegaly. Clinical Endocrinology, 101(2), 142-152. https://doi.org/10.1111/cen.15079

Vancouver

Bakker LEH, Verstegen MJT, Manole DC, Lu H, Decramer TJM, Pelsma ICM, et al. 18 F‐fluoro‐ethyl‐tyrosine PET co‐registered with MRI in patients with persisting acromegaly. Clinical Endocrinology. 2024;101(2):142-152. doi:10.1111/cen.15079

BibTeX
@article{Bakker2024,
  author = {Bakker, Leontine E H and Verstegen, Marco J T and Manole, Diandra C and Lu, Huangling and Decramer, Thomas J M and Pelsma, Iris C M and Kruit, Mark C and Verbist, Berit M and van de Ven, Annenienke and Gurnell, Mark and Ghariq, Idris and van Furth, Wouter R and Biermasz, Nienke R and Pereira Arias-Bouda, Lenka M},
  title = {18 F‐fluoro‐ethyl‐tyrosine PET co‐registered with MRI in patients with persisting acromegaly},
  journal = {Clinical Endocrinology},
  year = {2024},
  volume = {101},
  number = {2},
  pages = {142--152},
  doi = {10.1111/cen.15079}
}
Kostenlos starten →